Different studies have demonstrated that mTOR inhibitors might be beneficial in the treatment of Kaposi sarcoma, recurrent skin cancer, PTLD and renal cell carcinoma [18]. The gene discussed is MTOR; the disease is post-transplant lymphoproliferative disease.